



Vaccine Efficacy and Safety in Patients with Immune-Mediated Intestinal Diseases

Guest Editors:

Dr. Adi Lahat

Department of Gastroenterology,
Chaim Sheba Medical Center,
Affiliated to Tel Aviv University,
Tel Aviv, Israel

Dr. Kassem Sharif

Department of Gastroenterology,
Chaim Sheba Medical Center,
Affiliated to Tel Aviv University,
Tel Aviv, Israel

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editors

Vaccination plays a crucial role in preventing infectious diseases and promoting public health. However, individuals with immune-mediated intestinal diseases, such as inflammatory bowel disease, celiac disease, and other related conditions, present unique challenges and considerations regarding vaccine efficacy and safety. Understanding the specific challenges and considerations is essential for optimizing vaccination strategies in this vulnerable population.

This Special Issue aims to critically evaluate the current evidence regarding vaccine efficacy and safety in patients with immune-mediated intestinal diseases. It will explore the immune mechanisms underlying vaccine response alterations, the impact of immunosuppressive therapies on vaccine effectiveness, and the potential risks associated with vaccination in this population. Additionally, this Special Issue may discuss the available guidelines and recommendations for vaccination in this population, highlighting areas of uncertainty and areas that require further research.

We encourage the submission of original articles, systematic reviews, meta-analyses, short communications, and other types of articles related.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com